CLINICAL_TRIALS
safety_alert
· 2021-05-13
Clinical Trial Update: A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections [Phase 2]
Summary
A Phase 2 long-term safety study of subcutaneous tanezumab in osteoarthritis patients has been terminated; results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 | Status: TERMINATED | Results posted: 2021-05-13